Search Results
Your search for ,USE matches 11258 pages
Showing 401 - 450Study Shows Potential Benefits of AI-Assisted Classification in HER2-Low and HER2-Ultralow Breast Cancer
With the approval of HER2-targeted antibody-drug conjugate options for treating patients with breast cancer across different HER2 expression levels, accurate assessment of HER2 expression has become more important than ever. And a recent study may provide a solution to the challenge of accurate...
Study Finds GLP-1RAs May Lower Risk of Obesity-Related Cancers vs DPP-4 Inhibitors in Adults With Diabetes and Obesity
Studies have shown that being overweight or having obesity increases the risk of developing more than a dozen cancers, including meningioma, multiple myeloma, esophageal, thyroid, breast, gallbladder, stomach, liver, pancreas, kidney, ovarian, uterus, and colorectal.1 The presence of excess body...
Maintenance Therapy With Lurbinectedin Plus Atezolizumab Improves Survival Outcomes in Extensive-Stage Small Cell Lung Cancer
Maintenance treatment with the alkylating agent lurbinectedin plus the monoclonal antibody atezolizumab significantly improved both progression-free survival and overall survival compared with atezolizumab alone in patients with extensive-stage small cell lung cancer (SCLC), according to data...
Overall Survival Benefit Achieved With Inavolisib Plus Palbociclib and Fulvestrant in Advanced Breast Cancer
“Inavolisib plus palbociclib and fulvestrant significantly improved overall survival compared with placebo plus palbociclib/fulvestrant…. This is the first time overall survival has been significantly improved by a PI3K pathway–targeted drug,” said Nicholas Turner, MD, PhD, FRCP,FMedSci, who...
Inherited Genetic Differences May Predict Resistance to Immunotherapy in Metastatic Melanoma
Researchers may have uncovered genetic differences that may help predict response to immune checkpoint inhibitors among patients with metastatic melanoma, according to a recent study published by Monson et al in Nature Medicine. Background The investigation revolved around mitochondrial haplogroups ...
Use of Adjuvant Aspirin Reduces the Risk of Recurrence in PI3K-Mutated Colorectal Cancer
In the phase III ALASCCA trial, the use of adjuvant daily aspirin for 3 years reduced the risk of recurrence in colorectal cancer harboring PI3K pathway alterations by 51%, according to research in a Scandinavian population presented at the 2025 ASCO Gastrointestinal Cancers Symposium by Anna...
Treatment for Intractable Cancer Pain Pioneered
A novel therapy based on the plant-derived molecule resiniferatoxin could be a safe and effective agent for patients with difficult-to-control cancer pain, according to a recent study published by Mannes et al in NEJM Evidence. Background Resiniferatoxin is derived from Euphorbia resinifera, a...
Luis G. Paz-Ares, MD, PhD, on Extensive-Stage SCLC: Comparison of First-Line Regimens
Luis G. Paz-Ares, MD, PhD, of Hospital Universitario 12 de Octubre, H12O-CNIO Lung Cancer Unit, Universidad Complutense and Ciberonc, discusses data from the TIGOS trial, a phase III study comparing the first-line use of atigotatug (an antifucosyl-GM1 monoclonal antibody) plus nivolumab fixed-dose...
Preoperative THP Leads to pCR in Two-Thirds of Patients With Early-Stage HER2-Positive ER-Negative Breast Cancer
Patients with stage II and III (early-stage) HER2-positive breast cancer usually undergo preoperative therapy with multiagent chemotherapy in combination with anti-HER2 antibodies, followed by surgery. A less intensive, reduced-chemotherapy treatment approach is currently being evaluated in the...
Anti-Inflammatory Diet Could Benefit Survival Following Stage III Colorectal Cancer
Consuming an anti-inflammatory diet could improve posttreatment survival among patients with colorectal cancer compared with following a proinflammatory diet, according to new findings presented by Char et al at the 2025 ASCO Annual Meeting (Abstract LBA3509). The findings suggested that engaging...
Nicholas D. James, PhD, FRCP, MBBS, on Using AI to Identify Benefit From Prostate Cancer Therapy
Nicholas D. James, PhD, FRCP, MBBS, of The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, describes the use of a multimodal artificial intelligence (AI) model to identify benefit from second-generation androgen receptor pathway inhibitors in patients with high-risk...
Neoadjuvant Nivolumab and Chemotherapy Shows Significant OS Benefit at 5 Years in Resectable NSCLC
Neoadjuvant nivolumab plus chemotherapy significantly improved overall survival rates at 5 years compared with chemotherapy alone before surgery in patients with resectable non–small cell lung cancer (NSCLC), according to findings from the final analysis of the phase III CheckMate 816 trial. The...
Niraparib Plus Abiraterone in HRR-Mutant Metastatic Castration-Sensitive Prostate Cancer
Results from the international phase III AMPLITUDE clinical trial found that adding niraparib to abiraterone acetate plus prednisone (AAP) may help to slow cancer growth for people with metastatic castration-sensitive prostate cancer (mCSPC) with homologous recombination repair (HRR) gene...
New Application May Help Caregivers of Patients Undergoing Bone Marrow Transplant
A novel application could help to improve the quality of life among caregivers of patients undergoing bone marrow transplant, according to recent findings presented by Jacobs et al at the 2025 ASCO Annual Meeting (Abstract 11000) and simultaneously published in the Journal of Clinical Oncology....
Meta-Analysis Reveals How ICIs May Impact Solid Organ Transplant Responses
In the results of a meta-analysis of solid organ transplant recipients who have received immune checkpoint inhibitors as cancer treatment, the study authors concluded that immunotherapy may be “high risk yet promising” for these patients. These findings are being presented during the 2025 ASCO...
Elena Elez, MD, PhD, on Updated Survival Data From the BREAKWATER Trial
Elena Elez, MD, PhD, of Vall d’Hebron Institute of Oncology, presents updated overall survival data as well as progression-free survival data from the BREAKWATER trial of the first-line use of encorafenib, cetuximab, and mFOLFOX6 in BRAF V600E–mutant metastatic colorectal cancer (LBA3500).
Impact of Empirical Dietary Inflammatory Pattern on Survival Outcomes in Patients With Stage III Colon Cancer
Greater intake of a proinflammatory dietary pattern may be linked to worse overall survival in patients with stage III colon cancer who have undergone curative-intent resection. Sara K. Char, MD, a clinical fellow at Dana-Farber Cancer Institute, Boston, presented the results of a prospective...
ASCO 2025: Perioperative Durvalumab Boosts FLOT Chemotherapy Benefit for Patients With Gastric Cancers
Results from an international phase III clinical trial found that treating patients with stage II, III, and IVA resectable gastric cancer and gastroesophageal junction (GEJ) cancer with perioperative durvalumab and FLOT chemotherapy (fluorouracil, leucovorin, oxaliplatin, and docetaxel) helped...
Stuart J. Wong, MD, on Adjuvant Regimen in Resected HNSCC
Stuart J. Wong, MD, of the Medical College of Wisconsin and Plenary discussant, reviews findings from the phase III NIVOPOSTOP randomized trial, which investigated the adjuvant use of nivolumab added to radiochemotherapy for patients with resected head and neck squamous cell carcinoma who are at...
Sacituzumab Govitecan and Pembrolizumab Improve Disease Control in Advanced PD-L1–Positive Triple-Negative Breast Cancer
Results from an international phase III clinical trial show that treatment with sacituzumab govitecan-hziy and pembrolizumab helps patients with unresectable, locally advanced or metastatic PD-L1–positive triple-negative breast cancer live longer without disease progression compared with...
Trastuzumab Deruxtecan Improves Survival Outcomes in Patients With HER2-Positive Gastric/GEJ Cancer in Second-Line Setting
The international phase III DESTINY-Gastric04 clinical trial found that second-line treatment with fam-trastuzumab deruxtecan-nxki can help people with advanced HER2-positive gastric cancers that have grown during first-line treatment live about 3 months longer. These findings further support the...
Castor Oil
The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies sometimes used by patients with cancer. In this installment, Yen Nien (Jason) Hou, PharmD, DiplOM, LAc, and Jyothirmai Gubili, MS, focus...
Harm-Benefit Balance of Immune Checkpoint Inhibitor Treatment in Non–Small Cell Lung Cancer
In a study reported in JAMA Oncology, Heyward et al examined the harm-benefit balance of immune checkpoint inhibitor use across lines of treatment in non–small cell lung cancer (NSCLC). Study Details The retrospective cohort study, conducted in 2024, involved 2013 to 2019 Surveillance,...
Physical Function Acts as Predictor of Survival for Daratumumab-Based Therapy in Multiple Myeloma
Patients with multiple myeloma who had lower physical function scores at the time of treatment initiation demonstrated a greater benefit to daratumumab treatment than those with higher physical function scores, according to the results of a study published in the European Journal of Haematology....
Mortality Associated With Risk-Adapted Adjuvant Therapy in Postmenopausal Women With Early Breast Cancer
In a Danish Breast Cancer Group nationwide prospective cohort study reported in The Lancet Oncology, Jensen et al attempted to develop a prognostic standard mortality rate index to predict excess mortality based on risk-adapted adjuvant therapy in postmenopausal patients with early-stage breast...
Use of Niraparib in Patients With Advanced Melanoma
Researchers may have uncovered early indications of the clinical benefit of niraparib in patients with advanced melanoma whose tumors have specific genetic changes impacting DNA repair, according to a recent study published by Kim et al in JCO Precision Oncology. Background The U.S. Food and Drug...
I Have Stage IV Lung Cancer and Still Consider Myself the Luckiest Man in the World
Although I have spent the past 2 decades of my medical career as a primary care physician, educator, and researcher in conditions that disproportionately affect people of Asian descent, including lung cancer, I was still unprepared to hear the words “You have stage IV non–small cell lung...
Bringing Evidence-Based Integrative Medicine Into Everyday Oncology Practice
Despite the significant rise over the past 50 years in the use of evidence-based integrative medicine in conjunction with conventional cancer treatments—up from just 20% in the 1970s to about 80% in 20171—training opportunities in the fundamentals of this emerging field within the specialty of...
The Legal Impacts on Oncology Care of Prohibiting Diversity, Equity, and Inclusion Efforts
In January 2025, the Trump Administration issued executive orders asserting opposition to diversity, equity, and inclusion (DEI) programs on the federal level1,2 and rescinding Biden Administration orders that emphasized the importance of these efforts to promote equal opportunity across government ...
What Is the Value in Cost and Lives Saved of Cancer Screening and Prevention?
Several recent studies have shown the value of cancer screening in reducing the number of deaths from the disease. One study using computer modeling to estimate the number of cancer-related deaths that could be averted by increasing the use of U.S. Preventive Services Task Force (USPSTF)...
ASCO Congratulates 2025 Special Awards Recipients
ASCO and Conquer Cancer, the ASCO Foundation, will recognize researchers, patient advocates, philanthropists, teachers, and global oncology leaders who have reshaped cancer care around the world with the Society’s highest honors at the 2025 ASCO Annual Meeting. “The recipients of this year’s...
In Case You Missed It: Additional Abstracts of Interest in Cancer Research
Thousands of forward-looking research studies defined the 2025 American Association for Cancer Research (AACR) Annual Meeting. Here, aside from our fuller coverage of key presentations in The ASCO Post, we offer a snapshot of a few additional abstracts that may be of interest to cancer researchers...
Early-Stage Nonrectal Mismatch Repair–Deficient Tumors Respond to Neoadjuvant PD-1 Blockade, Facilitating Nonoperative Management
Mismatch repair–deficient (dMMR) tumors beyond those in the rectum may respond to PD-1 blockade in the neoadjuvant setting, offering the option of organ preservation in early-stage cancer regardless of the tumor type, researchers from Memorial Sloan Kettering (MSK) Cancer Center reported at the...
Together, We’re Building a Better Future for People With Cancer and for Our Profession
For more than 25 years, my goal as a community oncologist has been to ensure that all patients have access to the highest-quality cancer care. This is the future I stood for when I became ASCO’s 61st President and what I know our more than 50,000 members stand for. And I believe we will get there...
The Power of Translational Science to Transform the Lives of Patients Worldwide
Despite a 30-year history as an ASCO volunteer, for Eric J. Small, MD, FASCO, this past year as President-Elect has opened new perspectives on the organization he will soon lead as ASCO’s 62nd President, effective during the 2025 ASCO Annual Meeting, May 30–June 3, 2025, in Chicago. After serving...
GLP-1 RAs May Lower Risk of Obesity-Related Cancers
Studies have shown that having overweight or obesity increases the risk of developing more than a dozen cancers, including meningioma; multiple myeloma; and esophageal, thyroid, breast, gallbladder, stomach, liver, pancreatic, kidney, ovarian, uterine, and colorectal cancers. The presence of excess ...
Extensive-Stage SCLC: Lurbinectedin and Atezolizumab
Results from a global phase III clinical trial found that maintenance therapy with a combination of the alkylating agent lurbinectedin and the PD-L1 inhibitor atezolizumab improved survival in some patients with extensive-stage small cell lung cancer (SCLC) compared with maintenance therapy with...
Use of AI Assistance to Improve HER2 Breast Cancer Classifications
The accuracy of HER2 breast cancer scoring improved with the use of AI assistance, especially for patients with low and ultralow levels of HER2 expression, results from a multinational study showed. The findings were presented in a press briefing ahead of the 2025 ASCO Annual Meeting (Abstract...
ASCO and Google Cloud Announce AI-Powered Tool That Provides Faster, Interactive Access to ASCO’s Evidence-Based Clinical Guidelines
ASCO and Google Cloud have announced a collaboration to launch an artificial intelligence (AI)-based ASCO Guidelines Assistant. Developed with Google Cloud’s Vertex AI platform and Gemini models, the tool is poised to transform how oncology professionals access and use critical clinical...
WGS Liquid Biopsies for HPV-Associated Head and Neck Squamous Cell Carcinoma
Whole-genome sequencing (WGS)-based circulating tumor DNA (ctDNA) detection of human papillomavirus (HPV)-associated head and neck squamous cell carcinoma (HNSCC), termed HPV-DeepSeek by the study investigators, showed greater sensitivity, specificity, and diagnostic accuracy than any current...
Association Between Risk-Reducing Surgeries and Survival in Young BRCA Carriers With Breast Cancer
In an international cohort study reported in The Lancet Oncology, Blondeaux et al evaluated whether both risk-reducing mastectomy and risk-reducing salpingo-oophorectomy were associated with improved survival among women aged 40 or younger who have invasive breast cancer with germline BRCA1/2...
A High Proportion of U.S. Adults Are Behind on Cancer Screenings
Investigators have found that a large proportion of U.S. adults are behind on their cancer screenings, according to a new survey from the American Cancer Society Cancer Action Network (ACS CAN). Survey Methods and Findings In the Survivor Views Special Report: National Screening Survey,...
Recent Advances in Treating Diffuse Large B-Cell Lymphoma
The disease we now call diffuse large B-cell lymphoma (DLBCL) has gone by the names of reticulum cell sarcoma, diffuse histiocytic lymphoma, and diffuse large cell lymphoma, and included both lymphomas of B cells and T cells. We now know DLBCL is still heterogenous and some subtypes might benefit...
Risk of Gynecologic Cancers After 5 Years of Testosterone Use
Transmasculine and gender-diverse patients receiving testosterone as part of their hormone therapy may not be at an increased risk of developing gynecologic cancers in the first years of treatment, according to a recent study published by Vestering et al in eClinicalMedicine. Background Many...
Circulating Tumor DNA–Guided Risk Stratification in Colorectal Cancer: Evolving Evidence and Future Utility
Circulating tumor DNA (ctDNA) has emerged as a promising biomarker in colorectal cancer, offering dynamic insight into disease burden and recurrence risk. However, questions remain about its clinical utility and optimal application, as well as its equitable access across practice settings. At the...
NCCN Clinical Practice Guidelines in Oncology: 2025 Updates
The National Comprehensive Cancer Network (NCCN) released its first set of Clinical Practice Guidelines in Oncology (NCCN Guidelines®) in 1996, covering eight tumor types. Today, guidelines are available for more than 60 tumor types, subtypes, and related topics. During the NCCN’s 30th Annual...
AI Model Estimates Biological Age and Predicts Survival in Patients With Cancer
FaceAge, a deep learning system, was developed and validated to estimate biological age from photographs of faces. In a study published in The Lancet Digital Health, FaceAge showed the ability to predict short-term outcomes in patients with cancer. The study demonstrated that FaceAge could...
Revisiting Margin Width Guidelines for Ductal Carcinoma In Situ and the Role of Routine Reexcision
For postmenopausal women with hormone receptor–positive ductal carcinoma in situ (DCIS) treated with breast-conserving surgery, whole-breast irradiation, and adjuvant endocrine therapy, reexcision to achieve wider surgical margins (≥ 1 mm or ≥ 2 mm) may not be necessary, according to data presented ...
In Case You Missed It: Additional Abstracts of Interest From AACR
Thousands of forward-looking research studies defined the 2025 American Association for Cancer Research (AACR) Annual Meeting. Here, aside from our fuller coverage of key presentations in The ASCO Post, we offer a snapshot of a few additional abstracts that may be of interest to cancer researchers...
FDA Approves At-Home Self-Collection Device for Cervical Cancer Screening
Teal Health announced the U.S. Food and Drug Administration’s (FDA) approval of the Teal Wand™, an at-home vaginal sample self-collection device for cervical cancer screening in the United States. The Teal Wand is a prescription device that will soon be available at getteal.com for individuals aged ...
